Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Emma Greear

Rheumatology Kingsport, TN Doctor of Osteopathy

NPI 1467943845 CMS profile 5106339

3 Sheridan Sq, Kingsport, TN 37660

Open in the dashboard

General payments

$5,920

284 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emma Greear of Kingsport, TN is reported in the CMS Open Payments database as having received $5,920 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,175 114
2024 General $2,724 132
2023 General $863 34
2022 General $116 1
2020 General $13 1
2019 General $30 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emma Greear
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Emma Greear were reported at $2,175. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Emma Greear Rheumatology median Middle half National median
2019 $30 $744 $153–$2,687 $163
2020 $13 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $116 $627 $125–$2,303 $149
2023 $863 $741 $145–$2,524 $160
2024 $2,724 $830 $166–$2,660 $164
2025 $2,175 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,443 71 payments
  2. Amgen Inc. $1,129 61 payments
  3. Janssen Biotech, Inc. $544 20 payments
  4. UCB, Inc. $490 25 payments
  5. Novartis Pharmaceuticals Corporation $484 22 payments
  6. GlaxoSmithKline, LLC. $367 19 payments
  7. E.R. Squibb & Sons, L.L.C. $243 10 payments
  8. Lilly USA, LLC $222 7 payments
  9. AstraZeneca Pharmaceuticals LP $160 9 payments
  10. Mallinckrodt Hospital Products Inc. $105 4 payments
  11. Other $733 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,705 280 payments
  2. Education $215 4 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,281 65 payments
  2. TREMFYA $490 17 payments
  3. Enbrel $439 20 payments
  4. COSENTYX $410 19 payments
  5. BENLYSTA $367 19 payments
  6. Otezla $361 18 payments
  7. KRYSTEXXA $356 21 payments
  8. Cimzia $284 15 payments
  9. TAVNEOS $251 13 payments
  10. ORENCIA $243 10 payments
  11. Other $2,003 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

816

Median for Rheumatology: 1,511

Drug cost

$171,224

Median for Rheumatology: $1,139,948

Branded share of claims

19.4%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 21 $154,955
Hydroxychloroquine Sulfate Generic 134 $5,486
Colchicine Generic 52 $2,741
Methotrexate Methotrexate Sodium Brand 137 $2,656
Leflunomide Generic 48 $1,893
Mycophenolate Mofetil Generic 12 $782
Prednisone Generic 156 $687
Celecoxib Generic 30 $510
Diclofenac Sodium Generic 15 $340
Meloxicam Generic 84 $326

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$105,246

Medicare's payments for the services billed

Medicare patients

104

Average age 70

Services billed

5,470

81 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 31%
Chronic kidney disease 29%
Diabetes 27%
Osteoporosis 26%
Ischemic heart disease 23%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $395
$395 — —
KRYSTEXXA
  • Amgen Inc. $227
$227 — —
Enbrel
  • Amgen Inc. $226
$226 — —
TREMFYA
  • Janssen Biotech, Inc. $224
$224 — —
BENLYSTA
  • GlaxoSmithKline, LLC. $207
$207 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record